New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:07 EDTINSYInsys receives FDA orphan drug designation for pharmaceutical cannabidiol
Insys Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation to its pharmaceutical cannabidiol for the treatment of Lennox-Gastaut Syndrome, a rare pediatric-onset epilepsy. The company said, "We have the unique opportunity to test a controlled pharmaceutical CBD product for Lennox-Gastaut Syndrome, and our company is committed to advancing cannabinoid therapies that have the potential to provide significant medical benefits to patients across multiple indications. We expect to file an Investigational New Drug Application for CBD in 2H14."
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2014
10:05 EDTINSYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:22 EDTINSYInsys Therapeutics initiated with an Outperform at RBC Capital
Subscribe for More Information
September 29, 2014
07:14 EDTINSYInsys Therapeutics receives FDA orphan drug designation for CBD
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its pharmaceutical cannabidiol, CBD, for the treatment of glioma, which comprises approximately eighty percent of all malignant brain tumors. The ODD includes pontine glioma, a devastating form of primary brainstem glioma.
September 26, 2014
10:03 EDTINSYInsys Therapeutics receives orphan status for glioma treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use